Drugs / TQB3911
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06672263 | Nov 2024 → Sep 2026 overdue | chronic myeloid leukemia | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3911 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672263 ↗ |
| Action | Inhibit | “TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor.” NCT06672263 ↗ |
| Modality | Small molecule | “TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor.” NCT06672263 ↗ |
| Target | ABL1 | “TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor.” NCT06672263 ↗ |
| Target | BCR | “TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor.” NCT06672263 ↗ |